Supplements

Supplement Editor:
James B. Young, MD

Contents

Testing for B-type natriuretic peptide in the diagnosis and assessment of heart failure: What are the nuances?
James B. Young, MD; Natalie G. Correia, DO; Gary S. Francis, MD; Alan Maisel, MD; and Franklin Michota, MD

Supplement Editor:
James B. Young, MD

Contents

Testing for B-type natriuretic peptide in the diagnosis and assessment of heart failure: What are the nuances?
James B. Young, MD; Natalie G. Correia, DO; Gary S. Francis, MD; Alan Maisel, MD; and Franklin Michota, MD

Supplement Editor:
James B. Young, MD

Contents

Testing for B-type natriuretic peptide in the diagnosis and assessment of heart failure: What are the nuances?
James B. Young, MD; Natalie G. Correia, DO; Gary S. Francis, MD; Alan Maisel, MD; and Franklin Michota, MD

Supplement Editors:
Camille Sabella, MD, and Johanna Goldfarb, MD

Contents

New guidelines on acute otitis media: An overview of their key principles for practice
S. Michael Marcy, MD

From principles to practice: Case-based applications of the acute otitis media guidelines
Camille Sabella, MD; Johanna Goldfarb, MD; Scott Francy, MD; Jennifer K. Long, PharmD; and S. Michael Marcy, MD

Supplement Editors:
Camille Sabella, MD, and Johanna Goldfarb, MD

Contents

New guidelines on acute otitis media: An overview of their key principles for practice
S. Michael Marcy, MD

From principles to practice: Case-based applications of the acute otitis media guidelines
Camille Sabella, MD; Johanna Goldfarb, MD; Scott Francy, MD; Jennifer K. Long, PharmD; and S. Michael Marcy, MD

Supplement Editors:
Camille Sabella, MD, and Johanna Goldfarb, MD

Contents

New guidelines on acute otitis media: An overview of their key principles for practice
S. Michael Marcy, MD

From principles to practice: Case-based applications of the acute otitis media guidelines
Camille Sabella, MD; Johanna Goldfarb, MD; Scott Francy, MD; Jennifer K. Long, PharmD; and S. Michael Marcy, MD

Supplement Editor:
Zobair M. Younossi, MD, MPH

Contents

Foreword
Zobair M. Younossi, MD, MPH

The evolving treatment of chronic hepatitis C: Where we stand a decade out
Sherif Saadeh, MD, and Gary L. Davis, MD

Initial treatment for chronic hepatitis C: Current therapies and their optimal dosing and duration
Keyur Patel, MD, and John G. McHutchison, MD

Retreatment of patients who do not respond to initial therapy for chronic hepatitis C
Mitchell L. Shiffman, MD

Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: Anemia, neutropenia, and thrombocytopenia
Janus P. Ong, MD, and Zobair M. Younossi, MD, MPH

The role of hematopoietic growth factors in special populations with chronic hepatitis C: Patients with HIV coinfection, end-stage renal disease, or liver transplantation
Stevan A. Gonzalez, MD, and Ira M. Jacobson, MD

Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C
Catherine C. Crone, MD; Geoffrey M. Gabriel, MD; and Thomas N. Wise, MD

The role of physician extenders in managing patients with chronic hepatitis C
Harpreet Gujral, RN, MSN, CRNP; Carla Viscomi, RN, BSN; and Rochelle Collantes, MD, MPH

Supplement Editor:
Zobair M. Younossi, MD, MPH

Contents

Foreword
Zobair M. Younossi, MD, MPH

The evolving treatment of chronic hepatitis C: Where we stand a decade out
Sherif Saadeh, MD, and Gary L. Davis, MD

Initial treatment for chronic hepatitis C: Current therapies and their optimal dosing and duration
Keyur Patel, MD, and John G. McHutchison, MD

Retreatment of patients who do not respond to initial therapy for chronic hepatitis C
Mitchell L. Shiffman, MD

Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: Anemia, neutropenia, and thrombocytopenia
Janus P. Ong, MD, and Zobair M. Younossi, MD, MPH

The role of hematopoietic growth factors in special populations with chronic hepatitis C: Patients with HIV coinfection, end-stage renal disease, or liver transplantation
Stevan A. Gonzalez, MD, and Ira M. Jacobson, MD

Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C
Catherine C. Crone, MD; Geoffrey M. Gabriel, MD; and Thomas N. Wise, MD

The role of physician extenders in managing patients with chronic hepatitis C
Harpreet Gujral, RN, MSN, CRNP; Carla Viscomi, RN, BSN; and Rochelle Collantes, MD, MPH

Supplement Editor:
Zobair M. Younossi, MD, MPH

Contents

Foreword
Zobair M. Younossi, MD, MPH

The evolving treatment of chronic hepatitis C: Where we stand a decade out
Sherif Saadeh, MD, and Gary L. Davis, MD

Initial treatment for chronic hepatitis C: Current therapies and their optimal dosing and duration
Keyur Patel, MD, and John G. McHutchison, MD

Retreatment of patients who do not respond to initial therapy for chronic hepatitis C
Mitchell L. Shiffman, MD

Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: Anemia, neutropenia, and thrombocytopenia
Janus P. Ong, MD, and Zobair M. Younossi, MD, MPH

The role of hematopoietic growth factors in special populations with chronic hepatitis C: Patients with HIV coinfection, end-stage renal disease, or liver transplantation
Stevan A. Gonzalez, MD, and Ira M. Jacobson, MD

Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C
Catherine C. Crone, MD; Geoffrey M. Gabriel, MD; and Thomas N. Wise, MD

The role of physician extenders in managing patients with chronic hepatitis C
Harpreet Gujral, RN, MSN, CRNP; Carla Viscomi, RN, BSN; and Rochelle Collantes, MD, MPH